@entity3174 therapy and immune response to XXXX vaccine.

@entity1 @entity410 @entity683 @entity281 @entity3174
The effect of long-term @entity3174 therapy on the immune response to inactivated @entity683 vaccine was evaluated. The @entity1 were 31 white @entity1 who were receiving long-term @entity3174 therapy for @entity410 disorders and 31 age-matched controls. Prevaccination blood samples were collected, and the @entity1 were vaccinated subcutaneously with 0.5-mL inactivated whole-virion trivalent @entity683 vaccine. Venous blood samples were collected at 2, 4, 6, 9, 12, and 24 weeks after vaccination and stored at -20 degrees C until analysis. Total serum @entity3174 concentrations were measured by fluorescence polarization immunoassay. Immune response was measured by assaying the sera for hemagglutinin-inhibiting antibody to each of the three antigenic strains. Seroconversion was defined as a fourfold or greater increase in serum antibody titer following vaccination. In the @entity3174 -treated @entity1 , the mean (+/- S.D.) serum @entity3174 concentration before vaccination was 9.9 +/- 6.1 micrograms/mL. Prevaccination geometric mean titers were high enough in both groups to indicate that these @entity1 had been exposed to these or related antigens, and medical records confirmed that some of the @entity1 had been vaccinated the year before. The percent of @entity1 demonstrating seroconversion to each antigen at week 4 was low in both groups, and there were no significant differences between the two groups. The cumulative seroconversion responses observed up to week 24 were also not significantly different. Long-term @entity3174 therapy should not affect the efficacy of @entity683 vaccine in @entity1 who have been previously exposed to @entity281 or vaccination with identical or related strains.
